Value proposition

THE NEW STANDARD OF CARE FOR THE TARGETED TEMPERATURE MANAGEMENT OF PATIENTS

Neuron Guard is an Italian medical device company that has developed a technology to deliver hot and cold therapy for body surfaces.

One application is for selective brain temperature management. Other treatment options are focused on the need for local cooling or heating of body surfaces.

The company was formally founded in 2013 for the development of portable non invasive cooling and warming systems.

Our product CB240_Aurora is a portable hot or cold therapy system composed by a collar/wrap powered by a smart control unit.

In 2022 CB240_Aurora has obtained the CE mark as a class II medical device under MDR, and is now sold in 5 countries in Europe (Italy, Finland, Sweden, Czech Republic and Austria).

In 2023 Neuron Guard has obtained the ISO Certification 13485.

We are committed to collaborating with relevant stakeholders to identify the needs and adapt our product to make it as usable and effective as possible and compliant with all relevant regulations.

WHAT WE HAVE DONE SO FAR:
• IP: 11 patents (Italy, Europe, USA, China, New Zealand, Canada, Australia, Israel, Brazil, Russia and Qatar), 3 patent pending applications
• CLINICAL VALIDATION: A first-in-human pilot trial has successfully been completed at the Cambridge University Hospital Neurocritical Care Unit (Cambridge, UK), the largest Neurocritical Care Unit in Europe. The study demonstrated that CB240_Aurora is effective in achieving the clinical goal and being more brain selective than total body devices. The output of the trial has been published on Neurocritical Care (https://link.springer.com/article/10.1007/s12028-023-01800-7).
• PRODUCTION: CB240_Aurora is produced in Italy.
• COMMERCIALISATION: CB240_Aurora is currently sold through country distributors in Italy, Finland, Sweden, Czech Republic and Austria.